Key Takeaways
- Ozempic is the brand name for semaglutide, a once-weekly injection FDA-approved in December 2017 for adults with type 2 diabetes.
- It mimics GLP-1 (glucagon-like peptide-1), a natural gut hormone the body releases after meals to control blood sugar and appetite.
- Ozempic lowers blood sugar by stimulating insulin release after meals, suppresses glucagon (a hormone that raises blood sugar), slows gastric emptying, and reduces appetite by acting on the brain.
- In the SUSTAIN-6 cardiovascular outcomes trial, semaglutide reduced the risk of major adverse cardiovascular events by 26% in patients with type 2 diabetes and high cardiovascular risk.
- Average weight loss in SUSTAIN trials was 4.5 to 6.5 kg over 12 months at the 1.0 mg dose, even though Ozempic is not FDA-approved for weight loss.
- The same molecule, when prescribed for obesity rather than diabetes, is sold under the separate brand name Wegovy.
Direct answer (40-60 words)
Ozempic mimics the gut hormone GLP-1. It triggers insulin release after meals, suppresses glucagon, slows gastric emptying, and reduces appetite by acting on the brain. The combined effect is lower blood sugar in type 2 diabetes and meaningful weight loss as a secondary effect. It is given as a once-weekly subcutaneous injection.
Table of contents
- The 30-second answer
- What Ozempic is (the molecule and the brand)
- The four things Ozempic does inside the body
- What Ozempic is FDA-approved to treat
- How fast Ozempic starts working
- The clinical trial evidence: SUSTAIN program
- Cardiovascular and kidney benefits
- Weight loss as a secondary effect
- What Ozempic doesn't do
- Side effects and safety considerations
- Ozempic vs Wegovy vs Rybelsus
- FAQ
- Sources
- Footer disclaimers
What Ozempic is (the molecule and the brand)
The name on the box is Ozempic. The molecule inside the pen is semaglutide, a 31-amino-acid synthetic peptide engineered by Novo Nordisk to mimic GLP-1.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →GLP-1 is a hormone the small intestine releases after meals. It travels through the bloodstream and acts on the pancreas, stomach, and brain to control how the body handles food. The natural hormone has a half-life of about 2 minutes, which is too short to be a useful drug. Semaglutide is engineered with structural modifications, including a fatty acid side chain that binds to albumin in the blood, that extend its half-life to about 7 days.
That extended half-life is why Ozempic is dosed once weekly instead of multiple times a day.
Ozempic is sold by Novo Nordisk in pre-filled pen injectors. The pen contains semaglutide in 0.25 mg, 0.5 mg, 1.0 mg, or 2.0 mg per dose. Patients inject it under the skin (subcutaneously) once a week, on the same day each week, in the abdomen, thigh, or upper arm.
The four things Ozempic does inside the body
Ozempic does four things at once. These are the mechanisms that make it work.
1. It triggers insulin release after meals (only when blood sugar is high). This is the "glucose-dependent" part of how GLP-1 agonists work. After you eat, your blood sugar rises. Semaglutide tells the pancreatic beta cells to release insulin, but only in response to that rise. When blood sugar is normal or low, the drug is largely silent on insulin. This is why hypoglycemia risk is low with Ozempic alone, in contrast to insulin or sulfonylureas.
2. It suppresses glucagon. Glucagon is insulin's counterweight. The pancreas releases glucagon when blood sugar drops, and glucagon tells the liver to convert stored glycogen to glucose and release it into the blood. In type 2 diabetes, glucagon is often inappropriately high, which contributes to fasting hyperglycemia. Semaglutide dampens glucagon release, which lowers fasting blood sugar.
3. It slows gastric emptying. Food stays in the stomach longer. The normal stomach empties roughly half its contents in 90 minutes. On semaglutide, that half-empty time roughly doubles, especially after fatty meals. Slower emptying blunts the post-meal blood sugar spike (less glucose hits the bloodstream at once) and produces sustained fullness that reduces the next meal's portion size.
4. It acts on appetite centers in the brain. GLP-1 receptors are present in the hypothalamus and brainstem, the regions that regulate hunger and satiety. Semaglutide crosses the blood-brain barrier in small amounts and activates these receptors. Patients describe feeling full faster, staying full longer, and losing the food-noise quality of constant hunger thoughts. In some patients, the change is dramatic.
The combined effect is meaningful blood sugar control plus weight loss, both from the same once-weekly injection.
What Ozempic is FDA-approved to treat
Ozempic has two FDA-approved indications:
- As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus (FDA approval December 2017)
- To reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke) in adults with type 2 diabetes and established cardiovascular disease (FDA approval January 2020)
Ozempic is not FDA-approved for:
- Weight loss in non-diabetic adults (the same molecule, marketed as Wegovy, is approved for that)
- Type 1 diabetes
- Children under 18
- Pregnancy
Despite the diabetes-only label, Ozempic has been prescribed off-label for weight loss in non-diabetic adults at substantial volume. Off-label prescribing of FDA-approved drugs is legal but has driven shortages and insurance coverage friction.
How fast Ozempic starts working
The blood-sugar effect starts within days. Most patients see meaningful drops in fasting blood glucose within the first 1 to 2 weeks of starting at the 0.25 mg starter dose, even though that dose is sub-therapeutic for long-term control.
The full effect builds over weeks as the dose escalates:
- Week 1 to 4: 0.25 mg starter dose. Mild blood sugar effect. Side effects most prominent.
- Week 5 to 8: 0.5 mg dose. Meaningful glycemic and appetite effect. A1C starts dropping.
- Week 9 to 16: 1.0 mg if needed. Stronger weight loss signal. A1C continuing to drop.
- Week 17 onward: 2.0 mg if needed for additional A1C lowering. Full weight loss potential.
Weight loss typically begins around week 4 and accelerates from week 8 to month 6. A1C tends to drop most in the first 12 to 16 weeks and continues to improve gradually for up to a year.
If you don't see any blood sugar improvement after 8 weeks at a stable dose of 1.0 mg, that's a flag for a conversation with the prescriber. Either the dose is too low, the diagnosis is unusual, or the medication isn't a good fit.
The clinical trial evidence: SUSTAIN program
The SUSTAIN program is Novo Nordisk's series of phase 3 trials for semaglutide. SUSTAIN-1 through SUSTAIN-10 enrolled over 13,000 patients across multiple comparators.
| Trial | Comparator | A1C change (semaglutide 1.0 mg) | Weight change at 56 weeks |
|---|---|---|---|
| SUSTAIN-1 | Placebo | -1.5% | -4.5 kg |
| SUSTAIN-2 | Sitagliptin | -1.6% | -4.9 kg |
| SUSTAIN-3 | Exenatide ER | -1.6% | -5.6 kg |
| SUSTAIN-4 | Insulin glargine | -1.5% | -5.2 kg |
| SUSTAIN-5 | Placebo + insulin | -1.8% | -3.7 kg |
| SUSTAIN-6 | Placebo (CV outcomes) | -1.1% | -4.3 kg |
| SUSTAIN-7 | Dulaglutide | -1.5% | -6.5 kg |
Sources: Sorli et al., Lancet Diabetes Endocrinol, 2017 (SUSTAIN-1); Marso et al., N Engl J Med, 2016 (SUSTAIN-6); Pratley et al., Lancet Diabetes Endocrinol, 2018 (SUSTAIN-7).
Across the program, semaglutide consistently produced larger A1C reductions and larger weight loss than active comparators. The 1.0 mg dose was the most studied. The 2.0 mg high dose, added in 2022 based on the SUSTAIN-FORTE trial (Frias et al., Lancet Diabetes Endocrinol, 2021), provides modestly more A1C lowering and weight loss for patients who need it.
Cardiovascular and kidney benefits
SUSTAIN-6 was the cardiovascular outcomes trial. It enrolled 3,297 patients with type 2 diabetes and either established cardiovascular disease or high cardiovascular risk, and randomized them to semaglutide or placebo for a median of 2.1 years.
The headline results:
- 26% reduction in major adverse cardiovascular events (cardiovascular death, non-fatal MI, non-fatal stroke), HR 0.74, p<0.001 for non-inferiority and superiority
- Reduction driven primarily by non-fatal stroke (39% reduction) and non-fatal MI (26% reduction)
- 36% reduction in new or worsening nephropathy, HR 0.64, p=0.005
The cardiovascular and kidney findings were the basis for the second FDA indication (cardiovascular risk reduction) approved in 2020.
The mechanism for the cardiovascular benefit is not fully understood. Likely contributors include blood pressure reduction (about 4 mmHg systolic), modest LDL cholesterol reduction, weight loss, improved glycemic control, and possibly direct effects on vascular endothelium. The benefit is unlikely to be solely from weight or glucose lowering, since trials with similar weight or glucose effects from other agents haven't always produced the same cardiovascular reduction.
Weight loss as a secondary effect
Even though Ozempic is FDA-approved for type 2 diabetes, the weight loss it produces is meaningful. Across the SUSTAIN program, patients on the 1.0 mg dose lost an average of 4.5 to 6.5 kg over 56 weeks. The 2.0 mg dose produced slightly more.
For comparison, the same molecule at higher doses (2.4 mg weekly, marketed as Wegovy) produced 14.9% body-weight loss over 68 weeks in the STEP-1 trial in non-diabetic adults with obesity (Wilding et al., N Engl J Med, 2021). The Wegovy dose is over twice the maximum Ozempic dose, which is why the magnitude of weight loss differs.
For patients with type 2 diabetes who are also overweight or obese, the weight loss from Ozempic compounds the metabolic benefit. Weight loss improves insulin sensitivity, reduces hepatic glucose output, and improves blood pressure and lipids.
For patients without diabetes who want weight loss, Wegovy is the on-label option. Insurance coverage for Wegovy is often more friction than for Ozempic, which has driven the off-label prescribing pattern.
What Ozempic doesn't do
To set expectations correctly:
Ozempic does not:
- Cure type 2 diabetes. It controls blood sugar while you're taking it. Stopping the medication usually means blood sugar drifts back up over weeks to months.
- Replace diet and exercise. Both clinical trials and real-world data show better outcomes when patients also reduce caloric intake and increase activity.
- Work the same in everyone. Some patients lose 20% of body weight; others lose 5%. Some have major appetite suppression; others have only modest changes.
- Cause permanent weight loss. Weight typically rebounds when the medication is stopped, especially without behavioral changes during treatment.
- Treat type 1 diabetes. Ozempic requires functional pancreatic beta cells to work, and type 1 patients don't have them.
- Treat pregnancy-related conditions. Ozempic is not approved during pregnancy.
Ozempic is a medication that works while you take it. It is not a one-time fix, and it doesn't replace foundational lifestyle and dietary work.
Side effects and safety considerations
The most common side effects from the SUSTAIN trials:
| Side effect | Semaglutide 1.0 mg | Placebo |
|---|---|---|
| Nausea | 20% | 6% |
| Diarrhea | 13% | 7% |
| Vomiting | 10% | 2% |
| Constipation | 7% | 4% |
| Abdominal pain | 7% | 5% |
| Decreased appetite | 7% | 1% |
GI side effects peak in the first 4 weeks and during dose escalations. Most resolve as the body adapts.
Serious risks include:
- Pancreatitis (rare, around 0.3%)
- Gallbladder disease (rate roughly double placebo)
- Acute kidney injury secondary to severe vomiting or diarrhea
- Diabetic retinopathy complications in patients with pre-existing retinopathy
- Hypersensitivity reactions including anaphylaxis (rare)
Ozempic carries a boxed warning for thyroid C-cell tumors, based on rodent studies. The drug is contraindicated in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Ozempic vs Wegovy vs Rybelsus
All three contain semaglutide. They differ in dose, route, and FDA indication.
| Ozempic | Wegovy | Rybelsus | |
|---|---|---|---|
| Active ingredient | Semaglutide | Semaglutide | Semaglutide |
| Route | Subcutaneous injection | Subcutaneous injection | Oral tablet |
| Dosing schedule | Once weekly | Once weekly | Once daily |
| Maximum dose | 2.0 mg | 2.4 mg | 14 mg |
| FDA indication | Type 2 diabetes; cardiovascular risk reduction | Chronic weight management | Type 2 diabetes |
| FDA approval year | 2017 | 2021 | 2019 |
Switching between formulations is straightforward in principle but has practical wrinkles. Insurance often covers Ozempic but not Wegovy, or vice versa. The doses don't map 1:1 because oral semaglutide has lower bioavailability and weekly Wegovy has a different titration schedule.
FAQ
What does Ozempic actually do? Ozempic mimics the gut hormone GLP-1. It triggers insulin release after meals, suppresses glucagon, slows gastric emptying, and reduces appetite by acting on the brain. The combined effect is lower blood sugar in type 2 diabetes and weight loss as a secondary effect.
Is Ozempic an insulin? No. Ozempic is a GLP-1 receptor agonist, not insulin. It stimulates the pancreas to release the body's own insulin in response to meals. This is different from injecting insulin directly. The hypoglycemia risk with Ozempic alone is low.
How quickly does Ozempic work? Blood sugar improvements appear within 1 to 2 weeks. Weight loss typically begins around week 4 and accelerates over months 3 through 9. A1C usually drops most in the first 12 to 16 weeks.
Does Ozempic cause weight loss? Yes, as a secondary effect. The 1.0 mg dose typically produces 4 to 7 kg of weight loss over a year. The 2.0 mg dose produces slightly more. The same molecule at higher doses (2.4 mg, marketed as Wegovy) produces larger weight loss and is the on-label choice for patients without diabetes.
Is Ozempic safe long term? Long-term safety data extend over 5 years from the SUSTAIN-6 trial and beyond from real-world post-marketing surveillance. No new safety signals have emerged. The drug is generally well-tolerated when patients are screened for contraindications and monitored.
Does Ozempic lower blood pressure? Modestly. Across SUSTAIN trials, systolic blood pressure dropped by about 4 mmHg on average. The mechanism is partly weight loss, partly direct vascular effects.
Does Ozempic affect cholesterol? LDL cholesterol drops modestly (about 5 to 8%). Triglycerides drop more (about 12 to 15%). HDL changes are minimal. The lipid effect is modest but consistent across trials.
Why does Ozempic make you feel full? GLP-1 receptors in the hypothalamus and brainstem regulate hunger and satiety. Semaglutide activates these receptors and reduces hunger signaling. It also slows gastric emptying, so food sits in the stomach longer.
Can Ozempic cure diabetes? No. Ozempic controls blood sugar while you're taking it. It does not cure type 2 diabetes. Stopping the medication usually leads to blood sugar drifting back up over weeks to months.
What happens if I stop Ozempic? Blood sugar gradually returns toward pre-treatment levels over weeks to months. Weight typically rebounds, especially if behavioral changes weren't made during treatment. Some patients regain most of the lost weight within a year of stopping.
Is Ozempic the same as Wegovy? The active ingredient is the same (semaglutide). The doses, FDA indications, and packaging differ. Ozempic is approved for type 2 diabetes at doses up to 2.0 mg weekly. Wegovy is approved for chronic weight management at doses up to 2.4 mg weekly.
Is Ozempic safe in pregnancy? No. Ozempic is not recommended during pregnancy. The drug should be stopped at least 2 months before a planned pregnancy. If you become pregnant while on Ozempic, contact your provider promptly.
Sources
- Marso SP, et al. SUSTAIN-6: Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834-1844.
- Sorli C, et al. SUSTAIN-1: Efficacy and safety of once-weekly semaglutide monotherapy in patients with type 2 diabetes. Lancet Diabetes Endocrinol. 2017;5:251-260.
- Pratley RE, et al. SUSTAIN-7: Semaglutide vs dulaglutide once weekly in patients with type 2 diabetes. Lancet Diabetes Endocrinol. 2018;6:275-286.
- Frias JP, et al. SUSTAIN-FORTE: Efficacy and safety of once-weekly semaglutide 2.0 mg vs 1.0 mg in adults with type 2 diabetes. Lancet Diabetes Endocrinol. 2021;9:563-574.
- Wilding JPH, et al. STEP-1: Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384:989-1002.
- Ozempic Prescribing Information, Novo Nordisk, current revision.
- Wegovy Prescribing Information, Novo Nordisk, current revision.
- Rybelsus Prescribing Information, Novo Nordisk, current revision.
- Ahmann AJ, et al. SUSTAIN-3: Semaglutide vs exenatide ER. Diabetes Care. 2018;41:258-266.
- Aroda VR, et al. SUSTAIN-4: Semaglutide vs insulin glargine. Lancet Diabetes Endocrinol. 2017;5:355-366.
- American Diabetes Association. Standards of Medical Care in Diabetes 2025. Diabetes Care. 2025;48(Suppl 1).
- Drucker DJ. The biology of incretin hormones. Cell Metab. 2006;3:153-165.
Footer disclaimers (all 4 verbatim)
Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.
Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.
Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.
Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.
Talk to a licensed provider
Start your free assessment. A licensed provider reviews every request before anything is prescribed, and not everyone qualifies.
Start the assessment →